ArticleOPEN ACCESS

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Leukemia
DOI: 10.1038/s41375-025-02515-8
8Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

(Figure presented.)

Cite

CITATION STYLE

APA

Bewersdorf, J. P., Mi, X., Lu, B., Kuykendall, A., Sallman, D., Patel, M., … Stein, E. M. (2025, March 1). Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia. Springer Nature. https://doi.org/10.1038/s41375-025-02515-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free